| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5602534 | Heart, Lung and Circulation | 2017 | 7 Pages |
Abstract
The duration of CPB is linked to the release of biomarkers that indicate ischaemic-reperfusion damage to the gastrointestinal mucosa and endotoxaemia. I-FABP assay may help to identify patients presenting with intestinal damage, who are at risk of bacterial translocation.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Barbara PhD, Andrzej MD, PhD, Anna MD, PhD, Waldemar MD, PhD,